Ligases Enzyme Market Report 2025

The ligases enzyme market size has grown rapidly in recent years. It will grow from $3.23 billion in 2024 to $3.58 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to the initial discovery and development of ligase enzymes, growth of the biotechnology industry, increased understanding of DNA repair mechanisms, expansion of genetic engineering applications, and rise in demand for molecular diagnostics.

The ligases enzyme market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to the expansion of personalized medicine applications, growing focus on synthetic biology, adoption of ligase enzymes in drug development, increased demand for molecular diagnostics, and integration of ligases in next-generation sequencing. Major trends in the forecast period include the development of engineered ligases for specific applications, integration of ligase enzymes in CRISPR-based technologies, customization of ligase-based assays for research and diagnostics, rise of ligase-based isothermal amplification methods, adoption of ligase chain reaction (LCR) in diagnostic assays.

The rising incidence of cancer and genetic disorders is anticipated to drive the growth of the ligase enzyme market in the coming years. Cancer encompasses a range of diseases marked by the uncontrolled proliferation and spread of abnormal cells, while genetic disorders involve various medical conditions caused by abnormalities or mutations in an individual's genetic material, particularly DNA. Ligase enzymes play a crucial role in DNA replication, repair, and recombination. In the context of cancer, ligases facilitate the repair of damaged DNA, which can contribute to the unchecked growth of cells. Additionally, ligases can be employed to target and eliminate cells affected by genetic disorders. For instance, a report from the Australian Institute of Health and Welfare in July 2024 indicated an increase in diagnosed cancer cases in Australia, from 160,570 in 2022 to 164,694 in 2023, showcasing a significant rise over the year. This trend underscores the growing prevalence of cancer in the nation, with statistics revealing 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Furthermore, a February 2023 report by Gene People UK, a registered charity organization, stated that approximately 1 in 25 children in the UK are affected by a genetic condition, resulting in over 2.4 million individuals living with a genetic disorder. Annually, around 30,000 babies and children are newly diagnosed. Thus, the increasing prevalence of cancer and genetic disorders is propelling the growth of the ligase enzyme market.

An increase in research and development (R&D) activities is projected to drive the growth of the ligase enzyme market in the coming years. R&D encompasses the investigative efforts undertaken by companies or organizations to enhance existing products and processes or to create new ones. Ligase enzymes, commonly referred to as DNA ligases, are vital for joining DNA molecules together, making them indispensable tools for various R&D activities across multiple fields. For instance, a report from the Office for National Statistics in April 2024 revealed that the UK government's net expenditure on R&D (excluding contributions to the EU) rose to £15.5 billion ($19.375 billion) in 2022, reflecting a 10.5% increase from £14 billion ($17.5 billion) in 2021. Furthermore, in 2022, the total net expenditure on R&D, which included EU contributions and knowledge transfer activities, reached £16.4 billion ($20.5 billion), signifying an 8.9% increase from £15 billion ($18.75 billion) in 2021. Consequently, the rise in research and development activities is fueling the growth of the ligase enzyme market.

Major companies in the ligases enzyme market are advancing technologies like nanopore technologies to enhance the precision and efficiency of DNA sequencing and manipulation, thereby improving applications in genomics, synthetic biology, and personalized medicine. Nanopore technologies use nanopores to detect and analyze molecules, such as DNA or proteins, by measuring changes in ionic current as these molecules pass through the pore. For example, in February 2023, Eurofins Genomics, a US-based biotechnology firm, introduced the Express Oxford Nanopore Sequencing service. This service leverages Oxford Nanopore technology, enabling the sequencing of long DNA fragments. Such capabilities are especially advantageous for comprehensive genomic analyses, including metagenomics and structural variant detection.

Major companies in the ligases enzyme market are advancing technologies like the SAN HQ 2 enzyme to improve the efficiency and precision of nucleic acid manipulation in biomanufacturing processes. The SAN HQ 2 enzyme is specifically designed for biomanufacturing, effectively eliminating residual nucleic acids to enhance the purity and safety of processes such as viral vector production. For example, in December 2022, ArcticZymes Technologies ASA, a biotechnology firm based in Norway, launched the SAN HQ 2.0. This new product includes the SAN HQ 2 ELISA Kit, which represents a significant enhancement to ArcticZymes Technologies' portfolio. It demonstrates their commitment to providing reliable tools for quality control and compliance in biomanufacturing processes. This development not only addresses current industry demands but also positions ArcticZymes competitively in a market that prioritizes innovation and efficiency in bioprocessing.

In May 2022, QIAGEN N.V., a Germany-based provider of molecular testing solutions, acquired a majority stake in BLIRT S.A., a Poland-based biotechnology company known for manufacturing specialty ligase enzymes and reagents. This strategic acquisition is aimed at expanding QIAGEN's sample technology business by leveraging BLIRT's technology and expertise, thereby reinforcing QIAGEN's position in the life science industry. This strategic maneuver underscores the importance of inorganic growth strategies for gaining a competitive edge in the dynamic ligase enzyme market.

Major companies operating in the ligases enzyme market include BASF SE, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., GenScript, Promega Corporation, Oxford Nanopore Technologies Limited, Takara Bio Inc., New England Biolabs Inc., BioVision Inc., Enzo Life Sciences, Zymo Research, LGC Biosearch Technologies, Genetix Biotech Asia Pvt. Ltd., BLIRT S.A., Jena Bioscience, Bioline, Creative Enzymes, ArcticZymes Technologies ASA.

North America was the largest region in the ligases enzyme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the ligases enzyme market report during the forecast period. The regions covered in the ligases enzyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ligases enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ligase enzymes, a class of proteins essential for facilitating the union of two DNA strands, play a pivotal role in biotechnology and pharmaceuticals. Their significance extends to various cellular processes, notably DNA replication and protein synthesis.

Key types of ligase enzyme products include E. coli DNA ligase, T4 DNA ligase, mammalian ligases, and thermostable ligases. E. coli DNA ligase specifically refers to an enzyme sourced from Escherichia coli (E. coli) bacteria. These ligases are derived from diverse organisms, including microorganisms, animals, and plants. They are integral to a multitude of techniques, encompassing ligase chain reaction (LCR), ligase detection reaction (LDR), next-generation sequencing (NGS), repeat expansion detection (RED), rolling circle amplification (RCA), proximity ligation assay (PLA), molecular cloning, ligation-mediated PCR, and mutation detection. These versatile applications cater to a broad spectrum of end-users, including research laboratories and institutions, pharmaceutical and biopharmaceutical companies, as well as diagnostic laboratories.

The ligases enzyme market research report is one of a series of new reports that provides ligases enzyme market statistics, including ligases enzyme industry global market size, regional shares, competitors with a ligases enzyme market share, detailed ligases enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the ligases enzyme industry. This ligases enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. 

The ligases enzyme market consists of sales of hi-t4 DNA ligase, splintR ligase, salt-t4 DNA ligase, t7 DNA ligase, quick ligation kits, Taq DNA ligase, and electroLigase. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.